Boston (DbTechNo) - A new drug developed by both Lilly and Daiichi has been approved by the Food and Drug Administration (FDA).
The drug, known as Effient is a blood thinner and will surely rival Plavix, the leading blood thinner currently on the market.
In clinical trials, the drug showed the ability to prevent more heart attacks than rival Plavix, but was found to increase risk of internal bleeding.
Going by the brand name prasugrel, the drug will come with a blackbox warning of increased risk of fatal bleeding.
The FDA delayed their decision numerous times because of the risks associated with the drug.
Plavix is made by both Bristol-Myers Squibb and Sanofi-Aventis and is the second most sold drug in the world.
No comments:
Post a Comment